HUTCHMED (HCM) has released an update.
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
HUTCHMED has announced that China’s NMPA has accepted and granted Priority Review for the New Drug Application of tazemetostat, a novel treatment for relapsed or refractory follicular lymphoma. Already approved in the U.S. and Japan, tazemetostat’s China NDA is backed by promising results from a Phase II study. This development marks a significant step in HUTCHMED’s strategic collaboration with Epizyme for the drug’s research, development, and potential commercialization in Greater China.
For further insights into HCM stock, check out TipRanks’ Stock Analysis page.
